Hypoxemic Respiratory Failure clinical trials at UCLA
1 research study open to eligible people
In Line Aerosol Nebulization With High Flow
open to eligible people ages 18 years and up
The objective of ILAN is to assess the safety, feasibility and bronchodilator efficacy of in-line bronchodilator nebulizer delivery with VMN via HFNC system in hypoxemic respiratory failure patients treated with bronchodilators and compare this method to standard-nebulization using a jet nebulizer with a facial mask. The investigators hypothesized that aerosol nebulization using HFNC/VMN represents safer and more convenient approach in hypoxemic respiratory failure patients in comparison to conventional therapy while providing similar bronchodilator efficacy.
Los Angeles, California and other locations
Our lead scientists for Hypoxemic Respiratory Failure research studies include Igor Barjaktarevic, MD, PhD.
Last updated: